Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00541138 · ClinicalTrials.gov registry record · Phase 2
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00541138 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT00541138, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Tamoxifen may help carboplatin work better by making tumor cells more sensitive to the drug. PURPOSE: This phase II trial is studying the side effects of giving carboplatin and topotecan together with tamoxifen and to see how well it works in treating patients with central nervous system metastases or recurrent brain or spinal cord tumors.
Interventions
- DRUG carboplatin
- OTHER pharmacological study
- DRUG topotecan hydrochloride
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00541138
The ClinicalTrials.gov registry entry for NCT00541138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT00541138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00541138 about?
NCT00541138 is a clinical study titled "Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors". RATIONALE: Drugs used in chemotherapy, such as carboplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Tamoxifen may help carboplatin work better by making tumor cells more sensitive to the drug. PURPOSE: Th...
What is the current status of trial NCT00541138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2003-05. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00541138?
The interventions under investigation include: carboplatin (DRUG), pharmacological study (OTHER), topotecan hydrochloride (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00541138?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.